Research & Innovation
Welcome to Burley Labs, where cutting-edge science meets collaborative exploration
Advancing the development of next-generation therapeutics
Our Key Research Areas
Bioconjugate
Design
We are developing a new class of bioconjugates to deliver drug payloads to the cell target of interest.
Development of synthetic transcription factors to modulate the expression of target genes.
The primary research group’s focus areas are exploring the molecular basis of gene expression, and developing next generation therapeutics to correct for aberrant gene expression present in many diseases. We also develop new bioconjugation chemistries to deliver therapeutic payloads to the desired cell or tissue of interest.
The research team is dedicated to exploring gene expression, developing new drug delivery platform, and the identification of next generation therapeutics. We believe in the power of collaboration to drive impactful discoveries with our collaborators and industrial partners, and to support the academic growth of our team members.
Publications
Chemical biology research group addressing molecular mechanisms of biological processes relating to human disease.
69.
Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells
78.
Splice-switching small molecules: a new therapeutic approach to modulate gene expression
80
S-Adenosyl Methionine Cofactor Modifications Enhance the Biocatalytic Repertoire of Small Molecule C-Alkylation
104.
Gram-scale enzymatic synthesis of 2′-deoxyribonucleoside analogues using nucleoside transglycosylase-2
